Last updated on June 2010

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)


Brief description of study

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment. - Blood pressure control - Changing of adiponectin and plasminogen activator inhibitor-1 - Influence metabolizing and cardiac function, etc.

Detailed Study Description

The primary endpoints are: - blood pressure control - Adiponectin and plasma type1 plasminogen active inhibitor The secondary endpoints are - HOMA-IR - HbA1c - TNF-α - IL-6 - Plasma B-type natriuretic peptide - LVMI - E/A ratio - Tei-index - Apo-J

Clinical Study Identifier: NCT00790946

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.